Avalo Therapeutics (AVTX) Return on Capital Employed (2015 - 2026)
Avalo Therapeutics posted quarterly Return on Capital Employed of 81.97% for Q1 2026, down 4570.0% year-on-year from 1.83% in Q1 2025, and down 21.21% on a QoQ basis from 67.62% in Q4 2025.
Avalo Therapeutics (AVTX) has 12 years of Return on Capital Employed data on file, last reported at 81.97% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 4570.0% year-over-year to 81.97%; the trailing twelve-month figure through Mar 2026 stood at 81.97% (down 4570.0% YoY), and the FY2025 full-year result was 60.44%, up 2639.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 81.97%, down from 67.62% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 35.81% in Q1 2024 and bottomed at 291.53% in Q4 2022.
- The 5-year median for Return on Capital Employed is 136.2% (2022), against an average of 142.21%.
- The widest annual swing landed in 2022, when Return on Capital Employed tumbled 17056 bps; it then jumped 25543 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 291.53% in 2022, then jumped by 54 bps to 133.33% in 2023, then surged by 56 bps to 58.24% in 2024, then fell by 16 bps to 67.62% in 2025, then decreased by 21 bps to 81.97% in 2026.
- The last three Return on Capital Employed figures came in at 81.97% (Q1 2026), 67.62% (Q4 2025), and 56.41% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | -81.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81.97% |
| Dec 31, 2025 | -67.62% |
| Sep 30, 2025 | -56.41% |
| Jun 30, 2025 | -48.79% |
| Mar 31, 2025 | -36.27% |
| Dec 31, 2024 | -58.24% |
| Sep 30, 2024 | -147.19% |
| Jun 30, 2024 | -273.95% |
| Mar 31, 2024 | 35.81% |
| Dec 31, 2023 | -133.33% |
| Sep 30, 2023 | -137.59% |
| Jun 30, 2023 | -266.06% |
| Mar 31, 2023 | -219.63% |
| Dec 31, 2022 | -291.53% |
| Sep 30, 2022 | -286.69% |
| Jun 30, 2022 | -211.92% |
| Mar 31, 2022 | -136.20% |
| Dec 31, 2021 | -120.97% |
| Sep 30, 2021 | -132.68% |
| Jun 30, 2021 | -183.93% |
| Mar 31, 2021 | -264.84% |
| Dec 31, 2020 | -200.97% |
| Sep 30, 2020 | -130.66% |
| Jun 30, 2020 | -123.17% |
| Mar 31, 2020 | -171.66% |
| Dec 31, 2019 | -46.79% |
| Sep 30, 2019 | -29.10% |
| Jun 30, 2019 | -68.94% |
| Mar 31, 2019 | -82.45% |
| Dec 31, 2018 | -82.82% |
| Sep 30, 2018 | -95.52% |
| Jun 30, 2018 | 18.02% |
| Mar 31, 2018 | 30.63% |
| Dec 31, 2017 | 56.89% |
| Sep 30, 2017 | 134.72% |
| Jun 30, 2017 | -360.40% |
| Mar 31, 2017 | -676.08% |
| Dec 31, 2016 | -478.01% |
| Sep 30, 2016 | -465.54% |
| Jun 30, 2016 | -166.15% |
| Mar 31, 2016 | -102.64% |
| Dec 31, 2015 | -142.90% |